Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SUSMED,Inc. (4263.T)
JPY730.00
+6.00 (+0.83%)
JP JPX Healthcare Biotechnology
Address
MFPR Nihonbashi honcho Bldg 103-0023
Tokyo, JP
Tokyo, JP
CEO
Ryutaro Aoyama
Website
susmed.co.jp
IPO
2021-12-24
ISIN JP3319150003
Description
SUSMED,Inc. develops and sells therapeutic applications in Japan. It operates through DTx product business, and DTx platform business segments. The company develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease. It also develops and sells development platform for therapeutic apps and clinical trial systems. In addition, the company offers medical data analysis and consulting services. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY730.00
+6.00 (+0.83%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
231.6K
Beta
1.22
Float Shares
7.89M
Free Float %
46.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.12% | +7.15% | +7.38% | +1.64% | +9.65% | +13.16% | +60.03% | +81.47% | +81.47% | +81.47% | +81.47% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
730.00
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
89.44
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+35.2% ★ Q1'26: -59.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+17.0% Q1'26: -135.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-105.7% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-64.7% Q1'26: -42.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: -156.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.6% ★ Q1'26: +0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Jun 2022 actual |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
Jun 2029 1 Rev. Ana. 1 EPS Ana. |
Jun 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
316.87M
est: 313.00M (+1.2%)
|
530.65M
est: 522.00M (+1.7%)
|
342.58M
est: 346.00M (-1.0%)
|
462.99M
est: 479.00M (-3.3%)
|
775.00M
775.00M – 775.00M
+61.8% YoY
|
2.20B
2.20B – 2.20B
+183.9% YoY
|
2.45B
2.45B – 2.45B
+11.4% YoY
|
4.43B
4.43B – 4.43B
+80.8% YoY
|
5.39B
5.39B – 5.39B
+21.6% YoY
|
| EBITDA |
-227.10M
est: -214.54M (-5.9%)
|
-42.77M
est: -357.79M (+88.0%)
|
-358.99M
est: -237.14M (-51.4%)
|
-291.50M
est: -328.30M (+11.2%)
|
-531.17M
-531.17M – -531.17M
-61.8% YoY
|
-1.51B
-1.51B – -1.51B
-183.9% YoY
|
-1.68B
-1.68B – -1.68B
-11.4% YoY
|
-3.04B
-3.04B – -3.04B
-80.8% YoY
|
-3.69B
-3.69B – -3.69B
-21.6% YoY
|
| EBIT |
-229.15M
est: -216.67M (-5.8%)
|
-48.32M
est: -361.35M (+86.6%)
|
-364.98M
est: -239.51M (-52.4%)
|
-299.48M
est: -331.57M (+9.7%)
|
-536.46M
-536.46M – -536.46M
-61.8% YoY
|
-1.52B
-1.52B – -1.52B
-183.9% YoY
|
-1.70B
-1.70B – -1.70B
-11.4% YoY
|
-3.07B
-3.07B – -3.07B
-80.8% YoY
|
-3.73B
-3.73B – -3.73B
-21.6% YoY
|
| Net Income |
-233.48M
est: -332.50M (+29.8%)
|
-50.75M
est: -141.90M (+64.2%)
|
-357.42M
est: -460.12M (+22.3%)
|
-298.40M
est: -503.78M (+40.8%)
|
-188.08M
-188.08M – -188.08M
+62.7% YoY
|
782.54M
782.54M – 782.54M
+516.1% YoY
|
884.98M
884.98M – 884.98M
+13.1% YoY
|
2.25B
2.25B – 2.25B
+154.3% YoY
|
2.82B
2.82B – 2.82B
+25.4% YoY
|
| SGA |
309.28M
est: 357.77M (-13.6%)
|
394.67M
est: 596.67M (-33.9%)
|
452.48M
est: 395.49M (+14.4%)
|
476.57M
est: 547.52M (-13.0%)
|
885.86M
885.86M – 885.86M
+61.8% YoY
|
2.51B
2.51B – 2.51B
+183.9% YoY
|
2.80B
2.80B – 2.80B
+11.4% YoY
|
5.06B
5.06B – 5.06B
+80.8% YoY
|
6.16B
6.16B – 6.16B
+21.6% YoY
|
| EPS |
-15.90
est: -19.80 (+19.7%)
|
-3.09
est: -8.45 (+63.4%)
|
-21.41
est: -27.40 (+21.9%)
|
-17.77
est: -30.00 (+40.8%)
|
-11.20
-11.20 – -11.20
+62.7% YoY
|
46.60
46.60 – 46.60
+516.1% YoY
|
52.70
52.70 – 52.70
+13.1% YoY
|
134.00
134.00 – 134.00
+154.3% YoY
|
168.00
168.00 – 168.00
+25.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Ownership data is not available for this company yet.
Executive team
Top executives
EBIT / Employee
-6.96M
Shares Outstanding
16.86M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Takayuki Kohara | Director of Administration & Director | — | male |
| Taro Ueno | Chairman, Chief Executive Officer & President | — | male |
| Tomomitsu Motohashi | Chief Technology Officer & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4263.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
